# Blood Plasma Derivatives Market

> 血浆衍生物市场研究报告按类型[第八因子浓缩物、第九因子浓缩物、白蛋白、免疫球蛋白、抗凝血酶III浓缩物和新鲜冷冻血浆（FFP）]、应用（HIV、血友病A、血友病B、乙型肝炎、丙型肝炎、出血性疾病、低丙种球蛋白血症、免疫缺陷疾病及其他）、最终用户（医院和诊所、输血中心、诊断中心及其他）和地区（美洲、欧洲、亚太地区和中东及非洲）—预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.47%
- **2024:** $ 43.3 Billion
- **2025:** $ 46.6 Billion
- **2035:** $ 86.67 Billion
- **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Kedrion S.p.A. (IT), Bio Products Laboratory (GB), LFB Group (FR), Hualan Biological Engineering Inc. (CN)

**Report ID:** MRFR/Pharma/0817-HCR · **Pages:** 80 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** October 21, 2026

**URL:** https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325

---

## Market Summary

As per MRFR analysis, the Blood Plasma Derivatives Market Size was estimated at 43.3 USD Billion in 2024. The Blood Plasma Derivatives industry is projected to grow from 46.6 USD Billion in 2025 to 86.67 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.47% during the forecast period 2025 - 2035.

## Market Drivers

### Rising Demand for Immunoglobulins

The Global Blood Plasma Derivatives Market Industry experiences a notable surge in demand for immunoglobulins, primarily driven by their therapeutic applications in treating immune deficiencies and autoimmune disorders. As healthcare providers increasingly recognize the efficacy of immunoglobulins, the market is projected to reach 51.0 USD Billion in 2024.
 
This growth is indicative of a broader trend towards personalized medicine, where immunoglobulins play a crucial role in patient care. The increasing prevalence of [chronic diseases](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981) further fuels this demand, suggesting that the Global Blood Plasma Derivatives Market Industry is poised for sustained expansion.

### Growing Awareness of Rare Diseases

The Global Blood Plasma Derivatives Market Industry is witnessing an increase in awareness and diagnosis of rare diseases, which often require specialized plasma-derived therapies. As healthcare systems improve their capabilities to identify and treat these conditions, the demand for specific plasma derivatives, such as clotting factors and albumin, is expected to rise.
 
This trend is likely to contribute to the market's projected compound annual growth rate of 8.52% from 2025 to 2035. The growing focus on rare diseases underscores the importance of plasma derivatives in modern medicine, positioning the Global Blood Plasma Derivatives Market Industry for significant growth.

### Emerging Markets and Global Expansion

Emerging markets are playing a pivotal role in the growth of the Global Blood Plasma Derivatives Market Industry. Countries in Asia-Pacific and Latin America are experiencing rapid economic development, leading to increased healthcare spending and improved access to plasma-derived therapies.
 
This trend is likely to drive demand for various plasma products, contributing to the overall market growth. As these regions continue to develop their healthcare infrastructure, the Global Blood Plasma Derivatives Market Industry is expected to expand significantly, reflecting the changing dynamics of global healthcare.

### Regulatory Support for Plasma Products

Regulatory frameworks supporting the development and distribution of plasma-derived products are crucial for the Global Blood Plasma Derivatives Market Industry. Governments and health authorities are increasingly recognizing the therapeutic value of these products, leading to streamlined approval processes and enhanced funding for research and development.
 
This supportive environment encourages innovation and investment in the sector, which is essential for meeting the rising global demand for plasma derivatives. As a result, the market is expected to thrive, with projections indicating a substantial increase in value over the coming years.

### Advancements in Plasma Collection Technologies

Technological advancements in plasma collection and processing are significantly impacting the Global Blood Plasma Derivatives Market Industry. Innovations such as automated collection systems and improved separation techniques enhance the efficiency and safety of plasma donation. These advancements not only increase the yield of plasma derivatives but also improve donor experience, thereby attracting more individuals to donate.
 
As a result, the market is likely to benefit from a more robust supply chain, supporting the anticipated growth trajectory towards 125.3 USD Billion by 2035. This evolution in technology indicates a promising future for the Global Blood Plasma Derivatives Market Industry.

## Future Outlook

预计血浆衍生物市场将在2025年至2035年期间以6.47%的年均增长率增长，推动因素是对免疫球蛋白的需求增加和采集技术的进步。

到2035年，市场预计将实现强劲增长，成为生物制药领域的领导者。

## Segment Insights

### 按应用：免疫学（最大）与肿瘤学（增长最快）

血浆衍生物市场显示出多样化的应用谱系，免疫学在市场份额中占据领先地位。免疫学专注于与免疫系统相关的疾病，占据市场的相当大一部分，因为它包含了各种治疗和疗法。相反，肿瘤学作为一个快速增长的领域正在崛起，受到全球癌症发病率上升和创新疗法开发的推动。对有效癌症治疗选择的需求正在推动市场应用的边界。

免疫学：主导 vs. 肿瘤学：新兴

免疫学在血浆衍生物市场中脱颖而出，主要由于其在治疗自身免疫疾病和支持免疫疗法中的广泛应用。对免疫疗法的意识和进展增强了其市场地位。相比之下，肿瘤学被认为是一个新兴领域，因其对癌症治疗的高度关注而受到认可。利用血浆衍生物进行的肿瘤学疗法的持续研究和开发正在创造众多增长机会。随着制药公司继续创新和投资于癌症护理解决方案，肿瘤学在不断发展的市场格局中正成为一个关键领域。

### 按产品类型：白蛋白（最大）与免疫球蛋白（增长最快）

血浆衍生物市场被细分为多种产品类型，目前白蛋白在市场份额中占据领先地位。这占据了整体市场的相当大一部分，因为它在医疗治疗和疗法中的广泛应用。免疫球蛋白紧随其后，随着其在治疗免疫缺陷和其他疾病中的治疗优势受到关注，消费量不断增加。凝血因子和凝血因子浓缩物也为该细分市场做出了贡献，以满足特定的医疗需求，而纤维蛋白原作为一种独特的治疗应用产品正在崭露头角。在增长趋势方面，免疫球蛋白被认为是血浆衍生物中增长最快的细分市场，受到自身免疫疾病发病率上升和对免疫疗法需求增加的推动。医疗研究和技术的持续进步也促进了这一产品类型的扩展。同时，白蛋白由于其在市场中的既定存在而保持稳定，确保其在未来几年内作为主导参与者的角色。该细分市场的整体增长也得益于对血浆衍生产品的日益关注和全球医疗基础设施的扩展。

白蛋白（主导）与免疫球蛋白（新兴）

白蛋白在血浆衍生物市场中被定位为主导产品类型，因其在医疗治疗中的多样化应用，包括重症护理和外科手术。其在配方中的多功能性和安全性良好的记录使其成为医疗专业人员的首选。相反，免疫球蛋白被认为是该领域的新兴产品，因其在管理各种免疫学疾病中的有效性而受到推动。随着越来越多的临床应用被探索，免疫球蛋白的需求正在上升，特别是由于慢性疾病的增加需要免疫支持。随着研究继续揭示新的治疗潜力，这两种产品在市场格局中可能会保持重要的相关性。

### 按最终用途：医院（最大）与血库（增长最快）

在血浆衍生物市场中，医院代表了最大的细分市场，反映了它们在各种治疗中对血浆产品的关键需求，包括手术和创伤护理。该细分市场的可观市场份额受到医院入院人数增加和需要血浆衍生物进行有效管理的慢性疾病发病率上升的推动。此外，血库是增长最快的细分市场，响应了对血浆捐赠重要性和改进采集技术的高度关注。

医院（主导）与血库（新兴）

医院在血浆衍生物市场中发挥着主导作用，因为它们广泛使用血浆产品进行患者护理。它们在关键治疗和疗法中严重依赖这些衍生物，从而巩固了它们作为该市场主要消费者的地位。相比之下，血库是一个新兴细分市场，随着它们改善血浆采集流程和捐赠者外展项目而获得动力。血库的增长受到对血浆衍生疗法需求增加的推动，伴随着全球健康意识的提升，使它们成为血浆衍生物分销中的重要参与者。

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America continues to lead the Blood Plasma Derivatives Market, holding a significant share of 21.8% in 2024. The region's growth is driven by increasing demand for immunoglobulin therapies and advancements in plasma collection technologies. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring safety and efficacy in plasma-derived products. The rising prevalence of chronic diseases also fuels demand, making North America a pivotal market for blood plasma derivatives.

The competitive landscape in North America is robust, featuring key players such as Grifols, CSL Behring, and Takeda Pharmaceutical Company Limited. These companies are investing heavily in R&D to innovate and expand their product portfolios. The presence of advanced healthcare infrastructure and a well-established reimbursement framework enhances market attractiveness. As the region continues to innovate, it is expected to maintain its leadership position in the global market.

### Europe : Emerging Market with Growth Potential

Europe's Blood Plasma Derivatives Market is poised for growth, with a market size of €12.9 billion. The region benefits from a strong regulatory framework and increasing investments in healthcare infrastructure. Demand for plasma-derived therapies is rising, driven by an aging population and the prevalence of autoimmune diseases. European regulations ensure high safety standards, which further boosts consumer confidence and market growth. The region's collaborative research initiatives also play a crucial role in advancing plasma technology.

Leading countries in Europe include Germany, France, and the UK, where major players like Octapharma and LFB Group are actively expanding their operations. The competitive landscape is characterized by strategic partnerships and mergers aimed at enhancing product offerings. As the market evolves, Europe is expected to become a significant player in the global blood plasma derivatives sector, leveraging its strong research capabilities and regulatory support.

### Asia-Pacific : Rapidly Growing Market Dynamics

The Asia-Pacific region is witnessing rapid growth in the Blood Plasma Derivatives Market, with a market size of $7.5 billion. Factors such as increasing healthcare expenditure, rising awareness about plasma therapies, and a growing patient population are driving this expansion. Governments in the region are also implementing supportive regulations to enhance plasma collection and processing, which is crucial for meeting the rising demand for plasma-derived products. The region's diverse healthcare needs present significant opportunities for market players.

Countries like China and Japan are leading the charge, with companies such as Hualan Biological Engineering Inc. and Takeda Pharmaceutical Company Limited making substantial investments. The competitive landscape is evolving, with local players emerging alongside established global firms. As the region continues to develop its healthcare infrastructure, the demand for blood plasma derivatives is expected to surge, positioning Asia-Pacific as a key market in the global landscape.

### Middle East and Africa : Emerging Market with Challenges

The Blood Plasma Derivatives Market in the Middle East and Africa is still in its nascent stages, with a market size of $1.1 billion. The region faces challenges such as limited healthcare infrastructure and regulatory hurdles, which hinder market growth. However, increasing awareness of plasma therapies and rising healthcare investments are beginning to change the landscape. Governments are starting to recognize the importance of plasma-derived products, which could lead to more supportive regulations in the future.

Countries like South Africa and the UAE are showing potential for growth, with local companies and international players exploring opportunities. The competitive landscape is gradually evolving, with a focus on improving plasma collection and processing capabilities. As the region addresses its challenges, the Blood Plasma Derivatives Market is expected to gain traction, driven by increasing demand for therapeutic products and improved healthcare access.

## Competitive Benchmarking

The Blood Plasma Derivatives Market is characterized by a dynamic competitive landscape, driven by increasing demand for immunoglobulins and clotting factor concentrates. Key players are actively pursuing strategies that emphasize innovation, regional expansion, and strategic partnerships to enhance their market positions. For instance, Grifols (ES) has focused on expanding its product portfolio through research and development, while CSL Behring (AU) has been enhancing its global footprint by investing in new manufacturing facilities.
 
These strategies collectively contribute to a moderately fragmented market structure, where the influence of major players is significant but not overwhelming, allowing for niche players to thrive. In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and optimize logistics. This approach not only enhances operational efficiency but also aligns with the growing demand for rapid access to plasma-derived therapies. The competitive structure of the market appears to be moderately fragmented, with several key players exerting considerable influence, yet leaving room for smaller entities to carve out their niches through specialized offerings.
 
In November 2025, Takeda Pharmaceutical Company Limited (JP) announced a strategic partnership with a leading biotechnology firm to co-develop a novel immunoglobulin therapy. This collaboration is poised to leverage both companies' strengths in research and development, potentially accelerating the time-to-market for innovative therapies. Such partnerships are indicative of a broader trend where companies seek to pool resources and expertise to navigate the complexities of drug development in the plasma derivatives sector. 
 
In October 2025, Octapharma (CH) unveiled plans to invest €100 million in expanding its production capabilities in Switzerland. This investment is strategically significant as it aims to enhance the company's ability to meet the rising global demand for plasma-derived products. By increasing production capacity, Octapharma positions itself to capture a larger market share while ensuring a reliable supply of critical therapies.
 
In September 2025, Kedrion S.p.A. (IT) launched a new initiative focused on sustainability within its operations, aiming to reduce its carbon footprint by 30% by 2030. This move not only aligns with global sustainability trends but also enhances the company's reputation among environmentally conscious stakeholders. Such initiatives are becoming increasingly vital as consumers and healthcare providers prioritize sustainability in their purchasing decisions.
 
As of December 2025, the Blood Plasma Derivatives Market is witnessing a shift towards digitalization and AI integration, which are redefining competitive dynamics. Companies are increasingly forming strategic alliances to enhance their technological capabilities and streamline operations. The focus appears to be shifting from price-based competition to differentiation through innovation, technology, and supply chain reliability. This evolution suggests that future competitive advantages will likely hinge on the ability to deliver high-quality, innovative products while maintaining operational excellence.

## Recent News & Developments

In August 2026, It secures continuity of supply for a major U.S. immunoglobulin brand and signals ongoing inter-company commercial cooperation among two of the market's largest plasma fractionators, reducing near-term supply risk for patients on GAMMAKED. Kedrion Biopharma announced an extension of its long-standing commercial agreement with Grifols under which Kedrion continues to market GAMMAKED® (Immune Globulin Injection 10%) in the U.S. for primary immunodeficiency, ITP, and CIDP patients. (Source: [kedrion.us](https://www.kedrion.us/kedrion-biopharma-announces-the-extension-of-a-u-s-agreement-with-grifols-to-support-long-term-and-continued-access-to-gammaked/))

In July 2026, It's a significant emerging-market infrastructure play, expanding Takeda's global plasma-sourcing footprint and supporting local self-sufficiency in PDMPs — a growth strategy also being pursued by Grifols in Egypt. Takeda and the Indonesian Ministry of Health, together with two other ministries, announced a collaboration to build a domestic plasma ecosystem, marked by a fractionation license and an initial ~$30 million investment, including a pilot national plasma-donation network. (Source: [takeda.com](https://www.takeda.com/newsroom/newsreleases/2026/takeda-indonesia-plasma-collaboration/))

## Report Scope

| 2024年市场规模 | 433（亿美元） |
| --- | --- |
| 2025年市场规模 | 466（亿美元） |
| 2035年市场规模 | 866.7（亿美元） |
| 复合年增长率（CAGR） | 6.47%（2025 - 2035） |
| 报告范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 亿美元 |
| 主要公司简介 | 格里福斯（西班牙）、CSL Behring（澳大利亚）、武田制药有限公司（日本）、Octapharma（瑞士）、Kedrion S.p.A.（意大利）、Bio Products Laboratory（英国）、LFB Group（法国）、华兰生物工程股份有限公司（中国） |
| 涵盖的细分市场 | 应用、产品类型、最终用途 |
| 主要市场机会 | 治疗应用的进步推动血浆衍生物市场的增长。 |
| 主要市场动态 | 对免疫球蛋白的需求上升推动血浆衍生物市场的创新和竞争。 |
| 涵盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

<

## Frequently Asked Questions

**Q: 截至2024年，血浆衍生物市场的当前估值是多少？**
A: 血浆衍生物市场在2024年的估值为433亿美元。

**Q: 到2035年，血浆衍生物市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到866.7亿美元。

**Q: 在2025年至2035年的预测期内，血浆衍生物市场的预期年均增长率（CAGR）是多少？**
A: 在2025年至2035年的预测期内，市场的预期年均增长率为6.47%。

**Q: 哪些应用领域推动了血浆衍生物市场的增长？**
A: 应用领域包括免疫学、血液学、神经学、肿瘤学和传染病，估值范围从65亿到223.5亿美元。

**Q: 血浆衍生物市场的主要产品类型有哪些？**
A: 主要产品类型包括白蛋白、免疫球蛋白、凝血因子、凝血因子浓缩物和纤维蛋白原，估值范围从50亿到300亿美元。

**Q: 血浆衍生物市场的领先公司有哪些？**
A: 市场的主要参与者包括格里福斯、CSL贝赫林、武田制药有限公司、八达制药和凯德里昂S.p.A。

**Q: 哪些终端使用领域对血浆衍生物市场有贡献？**
A: 终端使用领域包括医院、诊所、研究实验室、血库和制药公司，估值范围从60亿到246.7亿美元。

**Q: 免疫球蛋白市场与其他产品类型相比如何？**
A: 免疫球蛋白的估值预计在150亿到300亿美元之间，使其成为领先的产品类型之一。

**Q: 肿瘤学领域在血浆衍生物市场中的重要性是什么？**
A: 肿瘤学领域预计将从90亿增长到180亿美元，表明其在市场扩展中的关键作用。

**Q: 研究实验室在血浆衍生物市场中的定位如何？**
A: 研究实验室预计将贡献70亿到140亿美元，突显其在市场中的重要性。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325*